CCG
VRTX icon

Catalina Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Catalina Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-873
Closed -$352K – 364
2024
Q4 		$352K Buy
873
+49
+6% +$22.7K 0.12% 178
2024
Q3 		$383K Buy
824
+43
+6% +$20.7K 0.13% 162
2024
Q2 		$366K Buy
781
+88
+13% +$38.2K 0.14% 154
2024
Q1 		$290K Buy
+693
New +$293K 0.12% 182

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Catalina Capital Group's VRTX Position: Q1 2025 in Review

Catalina Capital Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 873 shares — an estimated $352K sold.

Catalina Capital Group first reported a position in VRTX in Q1 2024 and held it in 4 quarters. The position peaked at $383K in Q3 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Catalina Capital Group reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Catalina Capital Group sold 873 Vertex Pharmaceuticals shares in Q1 2025, an estimated $352K.
  • Catalina Capital Group first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Catalina Capital Group's Vertex Pharmaceuticals position peaked at $383K in Q3 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.